How to Evaluate a Biotech Pipeline

The 5 dimensions of pipeline quality

1. Stage diversity. A balanced pipeline has assets at multiple stages so a single trial failure doesn't sink the company. Look for at least 1 commercial/Phase 3 asset + 2-3 Phase 1/2 follow-ons.
2. Indication diversity. Pipeline concentrated entirely in one indication (e.g., all oncology) carries indication-class risk. Diversified across 2-3 therapeutic areas reduces correlation.
3. Mechanism diversity. All assets working through the same mechanism = if the mechanism fails, every asset fails. Different mechanisms reduce platform risk.
4. Capital efficiency. How much R&D spend per asset advanced? Industry average is ~$200-500M to take a drug through Phase 3. Companies doing it for less are usually either capital-efficient or under-investing in quality.
5. Partnering activity. External validation through licensing deals or co-development agreements is independent confirmation that the science has legs.

How to assess each stage in the pipeline

• Discovery / preclinical: Hard to value; treat as call options. Don't pay much for these in the valuation.
• Phase 1: Worth maybe 5-15% of risk-adjusted Phase 3 NPV given low success rate.
• Phase 2: Worth 20-40% of risk-adjusted Phase 3 NPV. The biggest valuation re-rating happens here.
• Phase 3: Worth 40-70% of approval-state NPV.
• NDA filed / under review: Worth 60-85% of approval-state NPV depending on label clarity.

Red flags in pipeline evaluation

• Multiple "lead" assets — usually means none is actually leading
• Pipeline page hasn't been updated in 12 months (likely no progress)
• Assets that "could enter Phase 1 in 2H 2026" — vague timelines are usually not real
• Heavy reliance on platform marketing language ("our AI platform," "our DNA platform") without specific assets in trials
• All assets sourced from in-licensing (no internal discovery) — limits long-term value

Green flags

• Recent partnership with a Tier-1 pharma (Pfizer, Roche, J&J, Merck) — independent validation
• Repeated incremental positive data across multiple indications — suggests platform actually works
• Multi-year cash runway (24+ months) — buys time to execute
• Insider buying by management at current prices
• Detailed pipeline disclosure with specific milestones and timelines

Frequently Asked Questions

How many assets should a "good" biotech pipeline have?

At minimum, 3-5 assets across stages. Below that, you're a binary bet. Above 8-10 in early stage often means under-prioritization (can't advance them all). 5-7 well-staged assets is often the sweet spot.

Should I avoid one-product biotechs?

Not necessarily. One-product companies CAN be appropriate if (a) the product is approval-stage with high probability of success, (b) the indication has high commercial value, (c) you size the position appropriately for binary risk. But know what you're buying.

How do I value a biotech pipeline?

Most analysts build a sum-of-the-parts model: risk-adjusted NPV per asset (probability of approval × peak sales × duration of exclusivity − discounted to present value), summed across the pipeline. The Clinical Investor methodology page covers this in more detail.

What does "platform biotech" mean?

A company built around a technology (e.g., gene editing, mRNA, antibody-drug conjugates) that can generate multiple drugs. Higher long-term upside if the platform validates; higher binary risk if the platform fails. Examples: Moderna (mRNA), Crispr Therapeutics (CRISPR).

Related guides

• How to Read a Clinical Trial
• PDUFA Dates: Investor's Guide
• How to Invest in Biotech
• Biotech Catalyst Trading Strategy
• Clinical Trial Phases (1, 2, 3) Explained
• Biotech IPO Investor Guide
• FDA Approval Process Explained